Baird has increased its price target for Alignment Healthcare (ALHC, Financial) from $17 to $22, while maintaining an Outperform rating on the stock. Despite positive adjustments, the firm anticipates limited new stock buyers within the managed care and healthcare facilities sector until uncertainty around policy issues is resolved.
Baird does not foresee companies in the sector raising their 2025 guidance. They expect these firms to continue adopting a conservative approach, maintaining a financial cushion to manage potential challenges from Part D implications and broader economic conditions that could emerge later in the year.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Alignment Healthcare Inc (ALHC, Financial) is $17.89 with a high estimate of $23.00 and a low estimate of $9.00. The average target implies an downside of 6.49% from the current price of $19.13. More detailed estimate data can be found on the Alignment Healthcare Inc (ALHC) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Alignment Healthcare Inc's (ALHC, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Alignment Healthcare Inc (ALHC, Financial) in one year is $18.63, suggesting a downside of 2.61% from the current price of $19.13. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Alignment Healthcare Inc (ALHC) Summary page.
